Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Preferred Stock Liabilities (2020 - 2021)

Rani Therapeutics Holdings has reported Preferred Stock Liabilities over the past 2 years, most recently at $191.0 million for Q2 2021.

  • Quarterly results put Preferred Stock Liabilities at $191.0 million for Q2 2021, up 65.39% from a year ago — trailing twelve months through Jun 2021 was $191.0 million (up 65.39% YoY), and the annual figure for FY2020 was $184.7 million, changed.
  • Preferred Stock Liabilities for Q2 2021 was $191.0 million at Rani Therapeutics Holdings, roughly flat from $191.0 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for RANI hit a ceiling of $191.0 million in Q1 2021 and a floor of $115.5 million in Q2 2020.